VEGFA and neoplasm: Recurrent tumors can also be treated with bevacizumab (Avastin), which targets VEGF-A [8,9], or with recently approved tumor treating fields (TTFs) that are emitted by wearable devices in the form of electric impulses disrupting tumor cell division [10].